Security key
92941V209
- Security type / class
- Equity / COM
- Total 13F shares
- 36,472
- Total 13F value
- $84,980
- Share change
- +13,000
- SEC-reported price per share
- $2.33
- Number of holders
- 1
- Value change
- +$30,290
- Number of buys
- 1
Report period
Q4 2023
Institutions
1
Top holders
1
VYNE full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Yarrow Bioscience, Inc. SEC filings
Yarrow Bioscience, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 92941V209
Recent filing periods:
Ownership snapshot
Top reported holders of VYNE - VYNE THERAP. - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
AI Biotechnology LLC
Disclosed value leader
AI Biotechnology LLC
Comparable rows
0/5
Latest evidence
01 Nov 2023
3/4/5
13F
Highest disclosed value: $2,545,814
5 rows are not safely comparable across share classes.
Quick read
AI Biotechnology LLC has the largest disclosed position value at $2.55M.
0 of 5 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens AI Biotechnology LLC's linked filing trail.
Disclosed position value
Top 4
AI Biotechnology LLC
$2.55M
Andrew Saik
$265.5K
Matthew T. Wiley
$249.1K
STALEY CAPITAL ADVISERS INC
$94.8K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-5 of 5 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| AI Biotechnology LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$2,545,814
1,116,585 shares
|
— | 01 Nov 2023 |
| Andrew Saik |
3/4/5
Chief Financial Officer
|
—
denominator unverified
|
$265,547
116,468 shares
|
— | 28 May 2021 |
| Matthew T. Wiley |
3/4/5
Chief Commercial Officer
|
—
denominator unverified
|
$249,081
109,246 shares
|
— | 30 Jun 2021 |
| STALEY CAPITAL ADVISERS INC |
13F
Company
|
—
denominator unverified
|
$94,827
23,472 shares
|
— | 30 Sep 2023 |
| Rex Bright |
3/4/5
Director
|
—
denominator unverified
|
—
20,500 shares
|
— | 19 Jul 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
36,472
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2023 vs Q1 2026 Across Filers
Q1 2026 holders
1
Q4 2023 holders
1
Holder diff
0
| Investor | Q1 2026 Shares | Q4 2023 Shares | Share Diff | Share Chg % | Q1 2026 value | Q4 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend